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Abstracts / Osteoarthritis and Cartilage 23 (2015) A82eA416 A325meloxicam 15-mg tablets (2.0 vs 4.0 h, respectively). SoluMatrix
meloxicam 10 mg demonstrated approximately 33% lower overall sys-
temic exposure compared with conventional meloxicam 15-mg tablets.
As described for other NSAIDs, food decreased the rate but not the
overall extent of SoluMatrix meloxicam absorption (Table). Treatment-
related AEs included 1 case each of mild abdominal pain and mild
diarrhea in the SoluMatrix meloxicam 10mg (fed) group and 1 report of
mild somnolence in the SoluMatrix meloxicam 5 mg group. In the
separate phase 3 study in patients with OA pain, 350 (86.8%) of 403
patients completed the 12-week study. SoluMatrix meloxicam 5 mg
(mean [standard error] (SE) -36.5 [2.49]; P ¼ 0.0005) and 10 mg (-34.4
[2.68]; P¼0.0059; Table) provided signiﬁcantly greater pain relief as
measured by the primary efﬁcacy parameter compared with placebo
(-25.68 [2.64]). Patients in the SoluMatrix meloxicam 5mg (P¼0.0049)
and 10 mg (P¼0.0012) groups reported signiﬁcant differences in the
distribution of responses in the patient global impression of change
(from baseline) compared with placebo. Patients in the SoluMatrix
meloxicam 5 mg and 10 mg groups demonstrated a numerically greater
mean percentage reduction in pain (by NPRS) at 2 h (-33.44% for the 5
mg group; P¼0.0294 and -30.54% for the 10 mg group; P¼0.1357)
compared with placebo (-24.32%). Low-dose SoluMatrix meloxicam 10-
mg (mean± SE: 48.4±7.13 doses; P¼0.0013) and 5-mg (52.4±6.61
doses; P¼0.006) treated patients required signiﬁcantly fewer rescue
medication doses over 12 weeks compared with placebo (73.2±7.03
doses). Across SoluMatrix meloxicam groups, the most common AEs
(occurring in2% of patients) were diarrhea, headache, OA, and urinary
tract infection. No deaths or serious AEs were reported.Conclusions: Low-dose SoluMatrix meloxicam 5 and 10 mg, under
fasted conditions, provided comparable peak plasma levels, but with an
earlier time to peak plasma levels and with a 33% lower overall systemic
exposure compared with conventional meloxicam 15-mg tablets. Sol-
uMatrix meloxicam 5 and 10 mg once daily provided signiﬁcantly
greater relief from OA pain compared with placebo. These data suggest
that low-dose SoluMatrix meloxicam is a potentially promising treat-
ment option for adults with OA pain.
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Purpose: Introduction. Osteoarthritis (OA) is a chronic and degener-
ative condition. It affects not only cartilage but also bone, synovial and
periarticular soft tissue. Obesity is a recognized risk factor for knee OA
and weight loss reduces the risk of OA progression. Some studies have
examined the relationship between other components of body com-
position (BC), such as muscle mass and the risk of OA. Although several
studies have failed to determine a signiﬁcant relationship between fat
distribution and the risk of knee OA. We did not found studies that it
examined differences in body composition between early and late OA. If
there are difference, it could be part of the preoperative treatment
before undergo to total knee arthroplasty.Objective: To describe difference in BC between patients with early and
late knee OA in a Mexican population.
Methods: Patients and methods. The study was performed in a tertiary
hospital care. The patients in the early OA (EOA) had the following
inclusion criteria: patients with knee OA criteria according to American
College of Rheumatology, younger than 55 years old, a Kellgren-Law-
rence score less than or equal to 2 on the knee X-ray and without
previous surgery in the studied knee; Patients with late OA (LOA) group
had the following inclusion criteria: evaluation in the outpatients clinic
of joint surgery department, with a proposal of a primary joint
replacement surgery due to pain and/or disability due to knee OA,
Kellgren-Lawrence III or IV score on knee X-ray. Exclusion criteria in
EOA and LOA: patients with autoimmune inﬂammatory joint disease,
traumatic or congenital lesions. Clinimetric evaluation. All patients had
an interview to collect epidemiological data, joint function with
WOMAC knee index; All patients were evaluated using bioelectrical
impedance analysis in order to collect BC with multifrequency bio-
impedance (InBody 720®). Analysis.We used a descriptive and bivariate
analysis using appropriate to compare median between EOA vs. LOA.
Results: Results. 110 patients were evaluated, 56 with EOA and 54 LOA.
The EAO group were younger than LOA patients: median 48.5 vs. 65.5
years old (p ¼0.001). The women proportion was superior in both
groups: 71.8 women vs. 28.2 men. The EOA had a median of 11 edu-
cation years vs. 7 in LOA (p¼ 0.03). The OA evolutionwas 20.3 months in
EOA vs. 60 months in LOA (p¼0.001).
In table 1 we describe the BC in EOA vs. LOA The differences that we
found were only in female gender. In LOA group women had less total
lean mass, lean mass index and fatter mass index than EOA group. We
also found that women in LOA had less lean mass in the extremity
affected by OA compared to EOA group. We did not ﬁnd differences
between men gender groups. (Table 2).
Conclusions: Conclusions. The female patients with LOA in the knee
had more problems with the body compositions compared with the
female with EOA. The men groups (EOA vs. LOA) did not have differ-
ences. The lean mass is lower en female patient with LOA compared
with EAO. Probably It is one of the ﬁrst study that evaluate leg affected
composition between EOA vs. LOA; it ﬁnding could have preoperative
treatment implications.
